Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C61H82N8O9S
Molecular Weight:
1103.42
UNSPSC Code:
12352200
NACRES:
NA.21
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
BIR domain-targeting degrader of inhibitor of apoptosis proteins (IAPs) cIAP1/2 and XIAP.
CST626 is a degrader of cellular inhibitor of apoptosis (IAP) proteins (cIAP1/cIAP2/XIAP DC50 post 16h = 2.4/6.2/0.7 nM with >99% degradation observed post 3h treatment at 100 nM; MM1S cells) that effectively reduces the viability of hematological cancer cultures, including MM (IC50 post 96h = 8.5 nM/NCI-H929, 1.14µM/JJN3, 2.54 µM/RPMI-8826), AML (IC50 post 96h = 2.1 nM/MOLM13, 420 nM/K562, 1.17 µM/HEL) and DLBCL (IC50 post 96h = 1.6 nM/SUDHL6, 460 nM/DB, 1.69 µM/SUDHL4). CST626 is composed of a von Hippel-Lindau (VHL) ligand VH032 derivative linked to a monovalent Smac (DIABLO) AVPI motif-based IAP BIR domain-targeting ligand.
CST626 is a degrader of cellular inhibitor of apoptosis (IAP) proteins (cIAP1/cIAP2/XIAP DC50 post 16h = 2.4/6.2/0.7 nM with >99% degradation observed post 3h treatment at 100 nM; MM1S cells) that effectively reduces the viability of hematological cancer cultures, including MM (IC50 post 96h = 8.5 nM/NCI-H929, 1.14µM/JJN3, 2.54 µM/RPMI-8826), AML (IC50 post 96h = 2.1 nM/MOLM13, 420 nM/K562, 1.17 µM/HEL) and DLBCL (IC50 post 96h = 1.6 nM/SUDHL6, 460 nM/DB, 1.69 µM/SUDHL4). CST626 is composed of a von Hippel-Lindau (VHL) ligand VH032 derivative linked to a monovalent Smac (DIABLO) AVPI motif-based IAP BIR domain-targeting ligand.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuen Lam Dora Ng et al.
Journal of medicinal chemistry, 66(7), 4703-4733 (2023-03-31)
Proteolysis targeting chimeras (PROTACs) represent a new pharmacological modality to inactivate disease-causing proteins. PROTACs operate via recruiting E3 ubiquitin ligases, which enable the transfer of ubiquitin tags onto their target proteins, leading to proteasomal degradation. However, several E3 ligases are
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service